References
1. Cercek A., Roxburgh C.S.D., Strombom P., Smith J.J., Temple L.K.F., Nash G.M., et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018; 4 (6): e180071.
2. Cienfuegos J.A., Rodríguez J., Baixauli J., Chopitea A., García-Consuegra A., Abengózar M., et al. Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes. Rev Esp Enferm Dig. 2020; 112 (1): 16–22.
3. Al-Sukhni E., Milot L., Fruitman M., Beyene J., Victor J.C., Schmocker S., et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic re view and meta-analysis. Ann Surg Oncol. 2012; 19 (7): 2212-23.
4. Koizumi M., Yamada T., Shinji S., Yokoyama Y., Takahashi G., Iwai T., et al. Feasibility of neoadjuvant FOLFOX therapy without radiotherapy for baseline resectable rectal cancer. In Vivo. 2018; 32 (4): 937-43.
5. Engstrom P.F., Arnoletti J.P., Benson A.B. 3rd, Chen Y.J., Choti M.A., Cooper H.S., et al.; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Cancer Netw. 2009; 7 (8): 838-81.
6. Group E.G.W., Glimelius B. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007; 18 (suppl 2): ii23-4.
7. Glynne-Jones R., Wyrwicz L., Tiret E., Brown G., Ro-del C., Cervantes A., et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2018; 29 (suppl 4): iv263.
8. Cho S.H., Choi G.S., Kim G.C., Seo A.N., Kim H.J., Kim W.H., et al. Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: a propensity score analysis. Medicine (Baltimore). 2017; 96 (12): e6362.
9. Taylor F.G., Quirke P., Heald R.J., Moran B., Blomqvist L., Swift I., et al.; Group Multicenter Study. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011; 253 (4): 711-9.
10. Abraha I., Aristei C., Palumbo I., Lupattelli M., Tras-tulli S., Cirocchi R., et al. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev. 2018; 10: CD002102.
11. Zhao F., Wang J., Yu H., Cheng X., Li X., Zhu X., et al. Neoadjuvant radiotherapy improves overall survival for T3/4N+ M0 rectal cancer patients: a population-based study of 20 300 patients. Radiat Oncol. 2020; 15 (1): 49.
12. Lee J. B., Kim H.S., Jung I., Shin S.J., Beom S.H., Chang J.S., et al. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Trials. 2020; 21 (1): 320.
13. Wiltink L.M., Chen T.Y., Nout R.A., Kranen-barg E.M., Fiocco M., Laurberg S., et al. Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer. 2014; 50 (14): 2390-8.
14. Martella A., Willett C., Palta M., Czito B. The selective use of radiation therapy in rectal cancer patients. Curr Oncol Rep. 2018; 20 (6): 43.
15. Kusters M., Valentini V., Calvo F., Krempien R., Nieuwenhuijzen G., Martijn H., et al. Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases. Ann Oncol. 2010; 21 (6): 1279-84.
16. Fernandez-Martos C., Estevan R., Salud A., Pericay C., Gallen M., Sierra E., et al. Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. American Society of Clinical Oncology, 2012.
17. Hasegawa J., Mizushima T., Kim H.M., Miyake Y., Takemoto H., Tamagawa H., et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) with bevacizumab for locally advanced rectal cancer. American Society of Clinical Oncology, 2013.
18. Schrag D., Weiser M. R., Goodman K. A., Gonen M., Hollywood E., Cercek A., et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014; 32 (6): 513.
19. Ishii Y., Hasegawa H., Endo T., Okabayashi K., Ochiai H., Moritani K., et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluo-rouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010; 36 (11): 1061-5.
20. Tomida A., Uehara K., Hiramatsu K., Maeda A., Sakamoto E., Okada Y., et al.; the Nagoya Surgical Oncology Group. Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial. Int J Clin Oncol. 2019; 24 (4): 403-10.
21. Schwartz L.H., Litiere S., de Vries E., Ford R., Gwyther S., Mandrekar S., et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016; 62: 132-7.
22. Dworak O., Keilholz L., Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997; 12 (1): 19-23.
23. Kamiya T., Uehara K., Nakayama G., Ishigure K., Kobayashi S., Hiramatsu K., et al.; Nagoya Surgical Oncology Group, the Chubu Clinical Oncology Group. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. Eur J Surg Oncol. 2016; 42 (6): 829-35.
24. Uehara K., Hiramatsu K., Maeda A., Sakamoto E., Inoue M., Kobayashi S., et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013; 43 (10): 964-71.
25. Glynne-Jones R., Hall M.R., Lopes A., Pearce S., Goh V., Bosompem S., et al. BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). Heliyon. 2018; 4 (9): e00804.
26. Sato K., Miura T., Morohashi S., Sakamoto Y., Morohashi H., Yoshida T., et al. Comparable regional therapeutic effects between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced lower rectal cancer in terms of histopathological analysis. Mol Clin Oncol. 2019; 10 (6): 619-24.
27. Brouwer N.P.M., Stijns R.C.H., Lemmens V., Nag-tegaal I.D., Beets-Tan R.G.H., Futterer J.J., et al. Clinical lymph node staging in colorectal cancer; a flip of the coin? Eur J Surg Oncol. 2018; 44 (8): 1241-6.
28. Mizukami Y., Ueda S., Mizumoto A., Sasada T., Okumura R., Kohno S., et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg. 2011; 35 (4): 895-9.
29. Deng Y., Chi P., Lan P., Wang L., Chen W., Cui L., et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019; 37 (34): 3223-33.